ClinicalTrials.gov
public full text
Public Domain
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is a pilot preclinical study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Emicizumab and shared medical decision in patients living with hemophilia A.#923640
- Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform#837445
- NF-κB as a therapeutic target of rheumatoid arthritis#70029
- BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage#869337
- Acquired hemophilia A: an illustrated review based on the French National Guidelines#983958
Record · ID 892818
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive